Hypera S.A.
HYPMY
Other OTC4.00
USD
-0.04
- -
CIK
0001486749
ISIN
US44914U1060
CUSIP
44914U106
Return %
Stock
S&P500
1Y
-16.60
18.86
3Y
-57.00
64.57
5Y
-39.47
71.65
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Breno Toledo Pires de Oliveira
- Full Time Employees
- 10,564
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- Av. Magalhães de Castro, 4800 São Paulo SP Brazil 05676-120
- IPO Date
- Oct 15, 2010
- CIK
- 0001486749
- Website
- hypera.com.br
- Similar Companies
- Business
- Hypera S.A. operates as a leading Brazilian pharmaceutical company specializing in the development, manufacturing, and marketing of a diverse range of pharmaceutical and healthcare products. Its core business is divided into major units including prescription pharmaceuticals, over-the-counter (OTC) medicines, nutraceuticals, dermocosmetics, vitamins, and consumer health products. Key product lines under the prominent Mantecorp Farmasa brand cover diversified medical specialties in primary care, with products such as Addera D3, Nesina, Dramin, Alivium, Predsim, Lisador, and Rinosoro. Hypera also leads the Brazilian OTC market with well-established brands like Apracur, Benegrip, Buscopan, Coristina D Pro, Engov, Epocler, Estomazil, and Neosaldina. In addition, it offers nutraceuticals and vitamin supplements including Tamarine, Biotônico Fontoura, and Zero-Cal sweeteners. The company supports these products with a broad national sales and distribution network across Brazil, serving retail channels both directly and through distributors and wholesalers. Founded in 2001 and headquartered in São Paulo, Brazil, Hypera S.A. transitioned from its original name, Hypermarcas, in 2017 to emphasize its pharmaceutical focus. The company has undergone significant portfolio expansion and strategic refinement in recent years. Notably, it completed the acquisition of twelve drug brands from Sanofi in 2022, including four prescription products from the general medicine segment, enhancing its market position in several therapeutic areas. In 2021, it finalized the purchase of select OTC and non-core assets from Takeda, broadening its product base in Latin America with a transaction valued at approximately $825 million. Recently, Hypera reported continued portfolio strengthening with new product launches and brand extensions in skincare, consumer health, vitamins, endocrinology, respiratory, cardiology, and gastroenterology. In 2025, a new majority shareholder group consolidated a 53% controlling stake, signaling strategic governance realignment to support growth and market defenses. Hypera operates primarily in Brazil, covering pharmaceutical prescription products, OTC medicines, dermocosmetics, and nutritional products with an extensive pipeline of innovation exceeding 500 pipeline projects. Its broad therapeutic offerings address key medical specialties including gynecology, orthopedics, central nervous system, and cardiology. The company employs approximately 10,000 people across its operations and is listed on Brazil's B3 stock exchange under the ticker HYPMY. Hypera’s strategic portfolio focus, coupled with its consolidated leadership in consumer health and pharmaceuticals within Brazil, positions it as a dominant player in its home market with ongoing efforts toward expansion and product innovation.
Hypermarcas (OTCMKTS:HYPMY) Sees Large Increase in Short Interest
Hypermarcas (OTCMKTS:HYPMY) Short Interest Update
Hypermarcas (OTCMKTS:HYPMY) Short Interest Update
Hypermarcas (OTCMKTS:HYPMY) Shares Gap Up – Here’s What Happened
Hypera S.A. (HYPMY) Q3 2025 Earnings Call Transcript
Brazil's Hypera announces new majority stakeholder group
Hypera S.A. (HYPMY) Q4 2024 Earnings Call Transcript
Hypera: Short-Term Pain For Long-Term Gain
Hypera S.A.: Adding The Brazilian Pharma To Your Portfolio